Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
32.75
+0.77 (2.41%)
At close: Feb 2, 2026, 4:00 PM EST
33.73
+0.98 (2.99%)
After-hours: Feb 2, 2026, 6:20 PM EST
Spyre Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
95
Market Cap
2.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 886.00K | -1.44M | -61.96% |
| Dec 31, 2022 | 2.33M | -16.41M | -87.57% |
| Dec 31, 2021 | 18.74M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 3.89M | -1.32M | -25.30% |
| Dec 31, 2017 | 5.21M | 577.00K | 12.47% |
| Dec 31, 2016 | 4.63M | -1.46M | -23.94% |
| Dec 31, 2015 | 6.09M | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Telix Pharmaceuticals | 664.23M |
| Ultragenyx Pharmaceutical | 630.60M |
| Tarsus Pharmaceuticals | 366.10M |
| Arcus Biosciences | 240.00M |
| Wave Life Sciences | 109.23M |
| Beam Therapeutics | 55.70M |
| Ascentage Pharma Group International | 54.52M |
| Mesoblast | 17.20M |
SYRE News
- 10 days ago - Spyre Therapeutics Announces Grants of Inducement Awards - GlobeNewsWire
- 21 days ago - Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 - GlobeNewsWire
- 4 weeks ago - Spyre Therapeutics: Validated Targets, Optimized Delivery - Seeking Alpha
- 3 months ago - Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody - GlobeNewsWire
- 3 months ago - Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025 - GlobeNewsWire
- 3 months ago - Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million - GlobeNewsWire
- 3 months ago - Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock - GlobeNewsWire